Evidence map›Paper›PMID 33175313›Full record

ArticleBreast cancer research and treatment2021

Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset.

Swati Sakhuja, April Deveaux, Lauren E Wilson, Neomi Vin-Raviv, Dongyu Zhang, Dejana Braithwaite, Sean Altekruse, Tomi Akinyemiju

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2- Metastatic Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Observational
  2. Article
  3. Article
  4. Molecular subtypes as a prognostic breast cancer factor in women users of the São Paulo public health system, Brazil.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Swati SakhujaDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
April DeveauxDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Lauren E WilsonDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Neomi Vin-RavivSchool of Social Work, College of Health and Human Sciences, Colorado State University, Fort Collins, CO, USA.
Dongyu ZhangDepartment of Oncology, Georgetown University, Washington, DC, USA.
Dejana BraithwaiteDepartment of Oncology, Georgetown University, Washington, DC, USA.
Sean AltekruseDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Tomi AkinyemijuDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA. tomi.akinyemiju@duke.edu.ORCID http://orcid.org/0000-0002-1412-3234
Duke University · USGeorgetown University · USColorado State University · USNational Heart Lung and Blood Institute · USUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo examine patterns of de-novo metastases (mets) and association with breast cancer-specific mortality across subtypes and racial groups.

methodsNon-Hispanic (NH) Black and NH-White patients ages 40 years and older with primary breast cancer (BC) between 2010 and 2015 were examined. Multilevel logistic regression and Cox proportional hazards models were used to assess (1) odds of de-novo mets to specific sites by subtype, and (2) association of subtype with risk of BC mortality among patients with de-novo mets by race.

resultsA total of 204,941 BC patients were included in analysis. The most common de-novo mets site was to the bone, and overall prevalence of de-novo mets was higher among NH-Black (6.4%) versus NH-White (4.1%) patients. The odds of de-novo mets to any site were lower for TNBC (OR 0.68, 95% CI 0.62-0.73) and HR+/HER2- (OR 0.50, 95% CI 0.47-0.53) subtypes, but higher for HR-/HER2+ (OR 1.16, 95% CI 1.06-1.28) relative to HR+/HER2+ . De-novo mets to the brain only was associated with the highest mortality risk across all subtypes, ranging from a 13-fold increase (hazard ratio 13.45, 95% CI 5.03-35.96) for HR-/HER2+ to a 39-fold increase (hazard ratio 39.04, 95% CI 26.2-58.14) for HR+/HER2-.

conclusionSite and fatality of de-novo mets vary by subtype and by race. This information may help improve risk stratification and post-diagnostic surveillance to ultimately reduce BC mortality.

Indexed as

Breast NeoplasmsAdultBlack or African AmericanEthnicityFemaleHumansReceptors, EstrogenReceptors, ProgesteroneReceptors, EstrogenReceptors, ProgesteroneBreast cancerDe-novo metastasisHormone receptor statusMolecular subtypeMortalityRacial disparities

Identifiers

PMID33175313
OpenAlexW3102978286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.